Effect of supplementation in treatment of patients with multiple sclerosis

INTERVENTION: Control group: Placebo capsule, daily, for 16 weeks orally. Intervention 1: Intervention group: Probiotic capsule containing four strains of Bifidobacterium infantis (2×109 CFU/g), Lactobacillus reuteri (2×109 CFU/g), Lactobacillus casei (2×109 CFU/g), lactobacillus plantarum (2×109 CFU/g), lactobacillus fermentum (2×109 CFU/g), and bifidobacterium lactis (2×109 CFU/g), daily, for 16 weeks orally. Intervention 2: Control group: Placebo capsule, daily, for 16 weeks orally. Intervention group: Probiotic capsule containing four strains of Bifidobacterium infantis (2×109 CFU/g), Lactobacillus reuteri (2×109 CFU/g), Lactobacillus casei (2×109 CFU/g), lactobacillus plantarum (2×109 CFU/g), lactobacillus fermentum (2×109 CFU/g), and bifidobacterium lactis (2×109 CFU/g), daily, for 16 weeks orally. Treatment ‐ Drugs CONDITION: Multiple sclerosis Multiple sclerosis. ; Multiple sclerosis PRIMARY OUTCOME: 8‐hydroxydeoxyguanosine. Timepoint: At the beginning of the study and after 16 weeks of intervention. Method of measurement: Spectrophotometry. Glutathione. Timepoint: At the beginning of the study and after 16 weeks of intervention. Method of measurement: Spectrophotometry. Malondialdehyde. Timepoint: At the beginning of the study and after 16 weeks of intervention. Method of measurement: Spectrophotometry. Super oxide dismutase. Timepoint: At the beginning of the study and after 16 weeks of intervention. Method of measurement: Spectrophotometry. Total antioxidant capacity. Timepoint: At the beginning of the study and after 16 weeks of intervention. Method of measurement: Spectrophotometry. SECONDARY OUTCOME: Fasting blood sugar. Timepoint: At the beginning of the study and after 16 weeks of intervention. Method of measurement: Enzymatic kit. Hs‐CRP. Timepoint: At the beginning of the study and after 16 weeks of intervention. Method of measurement: ELISA kit. Insulin. Timepoint: At the beginning of the study and after 16 weeks of intervention. Method of measurement: ELISA. Interleukin 10. Timepoint: At the beginning of the study and after 16 weeks of intervention. Method of measurement: ELISA kit. Interleukin 6. Timepoint: At the beginning of the study and after 16 weeks of intervention. Method of measurement: ELISA kit. Nitric oxide. Timepoint: At the beginning of the study and after 16 weeks of intervention. Method of measurement: Spectrophotometry. Tumor necrosis factor alpha. Timepoint: At the beginning of the study and after 16 weeks of intervention. Method of measurement: ELISA kit. INCLUSION CRITERIA: Patients with multiple sclerosis; higher than 2 years of their disease; aged 20 to 60 years. Exclusion criteria: Unwillingness to cooperate.